Viyash Scientific Limited allotted 16,667 equity shares under its ESOP 2020 scheme at Rs. 86 per share to eligible employees. The allotment, approved by the Nomination and Remuneration Committee on April 02, 2026, increased the company's paid-up capital from Rs. 87,37,01,620 to Rs. 87,37,34,954. The total equity shares outstanding rose from 43,68,50,810 to 43,68,67,477 shares of Rs. 2 each, with the new shares ranking pari passu with existing equity shares.

Viyash Scientific Limited Allots 16,667 Equity Shares Under ESOP 2020 Scheme

Viyash Scientific Limited has completed the allotment of equity shares under its employee stock option plan, marking another step in its employee incentive program. The company, formerly known as Sequent Scientific Limited, announced the allotment through a regulatory filing dated April 02, 2026.

ESOP Allotment Details

The Nomination and Remuneration Committee of Viyash Scientific Limited approved the allotment through a resolution passed by circulation on April 02, 2026. The allotment involved issuing shares to eligible employees under the SeQuent ESOP 2020 scheme.

Parameter: Details Number of Shares Allotted: 16,667 equity shares Face Value: Rs. 2 per share Exercise Price: Rs. 86 per equity share Scheme: SeQuent ESOP 2020 Status: Fully paid

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The newly allotted shares rank pari passu in all respects with the existing equity shares of the company.

Metric: Before Allotment After Allotment Paid-up Capital: Rs. 87,37,01,620 Rs. 87,37,34,954 Number of Shares: 43,68,50,810 43,68,67,477 Face Value per Share: Rs. 2 Rs. 2

Corporate Information

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, operates from its registered office in Hyderabad, Telangana. The company maintains its stock exchange listings and continues to use the symbol VIYASH for trading purposes. The allotment was communicated to both BSE Limited and National Stock Exchange of India Limited as part of regulatory compliance requirements.

The company secretary and compliance officer, Yoshita Vora, signed the regulatory filing digitally, ensuring proper documentation of the share allotment process. This ESOP allotment reflects the company's ongoing commitment to employee participation in its equity growth.

Viyash Scientific Limited has issued a clarification regarding a date error in its previous intimation about the resignation of two Non-Executive Directors. The company, formerly known as Sequent Scientific Limited, submitted the clarification to BSE and NSE on March 31, 2026, addressing an inadvertent mistake in the covering letter of their earlier filing.

Date Error Clarification

The company acknowledged that in their March 30, 2026 intimation regarding director resignations, the covering letter incorrectly mentioned the date as March 30, 2025 instead of the correct date of March 30, 2026. This clarification was necessary to ensure accurate regulatory compliance and avoid any confusion among stakeholders.

Clarification Details: Information Original Filing Date: March 30, 2026 Incorrect Date Mentioned: March 30, 2025 Correct Date: March 30, 2026 Clarification Filed: March 31, 2026

Director Resignations Confirmed

The resignations of both Non-Executive Directors remain effective as originally announced. Dr. Fabian Kausche (DIN: 08976500) and Mr. Gregory Andrews (DIN: 08904518) stepped down from their positions on March 30, 2026, citing personal reasons and other commitments.

Director Details: Information Dr. Fabian Kausche: DIN: 08976500, Non-Executive Director Mr. Gregory Andrews: DIN: 08904518, Non-Executive Director Effective Date: March 30, 2026 Reason: Personal reasons and other commitments

Regulatory Compliance

The clarification was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Yoshita Vora signed the clarification document, expressing regret for any inconvenience caused by the date error. The company requested stock exchanges to take note of the correction and maintain accurate records.

Company Background

Both directors had expressed gratitude for their opportunity to serve on the board during their tenure. Dr. Fabian Kausche, based in Duluth, Georgia, USA, and Mr. Gregory Andrews both wished the company continued success and growth. The company has completed all necessary formalities related to these board changes in compliance with applicable regulations and has informed the Registrar of Companies and other regulatory authorities as required by law.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.